vs
Side-by-side financial comparison of Maison Solutions Inc. (MSS) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $27.6M, roughly 1.0× Maison Solutions Inc.). Maison Solutions Inc. runs the higher net margin — -18.0% vs -147.1%, a 129.1% gap on every dollar of revenue. On growth, Maison Solutions Inc. posted the faster year-over-year revenue change (-10.9% vs -67.6%).
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
MSS vs SPRY — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $28.1M |
| Net Profit | $-5.0M | $-41.3M |
| Gross Margin | 23.4% | — |
| Operating Margin | -4.9% | -147.6% |
| Net Margin | -18.0% | -147.1% |
| Revenue YoY | -10.9% | -67.6% |
| Net Profit YoY | -1840.5% | -182.8% |
| EPS (diluted) | $-0.23 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.6M | $28.1M | ||
| Q3 25 | $27.2M | $32.5M | ||
| Q2 25 | $34.4M | $15.7M | ||
| Q1 25 | $32.3M | $8.0M | ||
| Q4 24 | $29.4M | $86.6M | ||
| Q3 24 | $28.2M | $2.1M | ||
| Q2 24 | $16.9M | $500.0K | ||
| Q1 24 | $13.6M | $0 |
| Q4 25 | $-5.0M | $-41.3M | ||
| Q3 25 | $-1.5M | $-51.2M | ||
| Q2 25 | $-287.4K | $-44.9M | ||
| Q1 25 | $1.0M | $-33.9M | ||
| Q4 24 | $-256.0K | $49.9M | ||
| Q3 24 | $700.9K | $-19.1M | ||
| Q2 24 | $-2.8M | $-12.5M | ||
| Q1 24 | $-549.0K | $-10.3M |
| Q4 25 | 23.4% | — | ||
| Q3 25 | 24.1% | — | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | 21.8% | — | ||
| Q4 24 | 26.9% | — | ||
| Q3 24 | 28.9% | — | ||
| Q2 24 | 13.0% | — | ||
| Q1 24 | 23.4% | — |
| Q4 25 | -4.9% | -147.6% | ||
| Q3 25 | 0.7% | -163.7% | ||
| Q2 25 | -15.9% | -302.9% | ||
| Q1 25 | 3.7% | -466.3% | ||
| Q4 24 | 3.2% | 54.5% | ||
| Q3 24 | 7.3% | -1051.6% | ||
| Q2 24 | -14.4% | -3068.0% | ||
| Q1 24 | -2.3% | — |
| Q4 25 | -18.0% | -147.1% | ||
| Q3 25 | -5.7% | -157.4% | ||
| Q2 25 | -0.8% | -285.6% | ||
| Q1 25 | 3.1% | -425.7% | ||
| Q4 24 | -0.9% | 57.7% | ||
| Q3 24 | 2.5% | -925.0% | ||
| Q2 24 | -16.4% | -2503.2% | ||
| Q1 24 | -4.0% | — |
| Q4 25 | $-0.23 | $-0.41 | ||
| Q3 25 | $-0.08 | $-0.52 | ||
| Q2 25 | $-0.02 | $-0.46 | ||
| Q1 25 | $0.06 | $-0.35 | ||
| Q4 24 | $-0.01 | $0.52 | ||
| Q3 24 | $0.04 | $-0.20 | ||
| Q2 24 | $-0.16 | $-0.13 | ||
| Q1 24 | $-0.03 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | $2.6M | $96.4M |
| Stockholders' EquityBook value | $11.6M | $114.3M |
| Total Assets | $75.4M | $327.7M |
| Debt / EquityLower = less leverage | 0.22× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | $1.1M | $288.2M | ||
| Q2 25 | $775.4K | $240.1M | ||
| Q1 25 | $445.4K | $275.7M | ||
| Q4 24 | $355.7K | $314.0M | ||
| Q3 24 | $588.9K | $204.6M | ||
| Q2 24 | $2.1M | $218.7M | ||
| Q1 24 | $9.4M | $223.6M |
| Q4 25 | $2.6M | $96.4M | ||
| Q3 25 | $2.6M | $96.2M | ||
| Q2 25 | $2.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $2.5M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | $11.6M | $114.3M | ||
| Q3 25 | $10.1M | $147.7M | ||
| Q2 25 | $11.7M | $192.3M | ||
| Q1 25 | $12.0M | $229.0M | ||
| Q4 24 | $10.9M | $256.8M | ||
| Q3 24 | $11.2M | $201.0M | ||
| Q2 24 | $10.5M | $215.2M | ||
| Q1 24 | $13.3M | $223.9M |
| Q4 25 | $75.4M | $327.7M | ||
| Q3 25 | $73.3M | $372.8M | ||
| Q2 25 | $77.4M | $313.5M | ||
| Q1 25 | $82.7M | $327.3M | ||
| Q4 24 | $82.7M | $351.2M | ||
| Q3 24 | $82.1M | $217.6M | ||
| Q2 24 | $82.4M | $222.0M | ||
| Q1 24 | $44.2M | $227.6M |
| Q4 25 | 0.22× | 0.84× | ||
| Q3 25 | 0.26× | 0.65× | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-43.5M | ||
| Q3 25 | $1.1M | $-47.0M | ||
| Q2 25 | $-1.6M | $-39.6M | ||
| Q1 25 | $1.7M | $-40.7M | ||
| Q4 24 | $1.1M | $42.0M | ||
| Q3 24 | $3.6M | $-14.5M | ||
| Q2 24 | $-2.6M | $-7.3M | ||
| Q1 24 | $-1.4M | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.66× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 5.12× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
